Erlin-2 Antibodies

Erlin-2 (ERLIN2)

Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs) such as ITPR1 (PubMed:19240031, PubMed:17502376). Promotes sterol-accelerated ERAD of HMGCR probably implicating an AMFR/gp78-containing ubiquitin ligase complex (PubMed:21343306).

Involved in regulation of cellular cholesterol homeostasis by regulation the SREBP signaling pathway. May promote ER retention of the SCAP-SREBF complicated (PubMed:24217618).

Gene Information

Human
Gene Name:	ERLIN2
Uniprot:	O94905
Entrez:	11160

Family

Belongs to:
band 7/mec-2 family

Alternative Names

C8orf2SPFH domain-containing protein 2; Endoplasmic reticulum lipid raft-associated protein 2; ER lipid raft associated 2; Erlin-2; MGC87072; NET32; SPFH domain family, member 2; SPFH2chromosome 8 open reading frame 2; Stomatin-prohibitin-flotillin-HflC/K domain-containing protein 2

Molecular Weight

Mass (kDA):
37.84 kDA

Genomic Context

Human
Location:	8p11.23
Sequence:	8; NC_000008.11 (37736627..37758422)

Tissue Specificity

Ubiquitous.

Subcellular Localizations

Endoplasmic reticulum membrane; Single-pass type II membrane protein. Associated with lipid raft-like domains of the endoplasmic reticulum membrane.

Diseases

• Malignant Neoplasms
• Malignant Neoplasm Of Breast
• Spastic Paraplegia, Hereditary
• Paraplegia
• Muscle Spasticity
• Cell Transformation, Neoplastic
• Spastic Paraplegia
• Neurodegenerative Disorders
• Weakness
• Motor Neuron Disease
• Mammary Neoplasms
• Nerve Degeneration

• Optic Atrophy
• Carcinoma, Transitional Cell
• Sclerosis
• Primary Lateral Sclerosis
• Polyneuropathy
• Dementia

Interacting Proteins

• AMFR
• ERLIN1
• TMUB1

Pathways

• Rna Interference
• Cell Growth
• Localization
• Transport
• Cell Proliferation
• Cell Death
• Protein Maturation
• Lipid Storage
• Regulation Of Gene Expression

• Transcytosis
• Cholesterol Homeostasis
• Oncogenesis

PTMs

• Ubiquitination

• Biotinylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ERLIN2

Best Uses of the ERLIN2 Marker

This page will provide information about Steven Boster and his ERLIN2 marker. You'll learn about his life, the ERLIN2 marker, and histology. You will also learn about primary antibodies, histology, and other topics. So, which biomarker is best for you? What are Boster’s products then?

ERLIN2 marker

ERLIN2, also known as SPFH2, is a member of the SPFH protein family. This family of proteins is found in cholesterol-rich, detergent resistant membranes. It is involved in the ERAD pathway which mediates cell homeostasis by the degradation of abnormal and dysfunctional proteins. Understanding the role ERLIN2 plays in disease development and LUAD is critical for the identification of new therapeutic targets.

1996 was the first year that the ERLIN2 marker had been identified. It was discovered in 1996 that human ERLIN2 forms can be distinguished based on their different amino acid compositions. A single ERLIN2 mutated transcription is susceptible to nonsense mediated mRNA decay. This is because a premature stop codon was located less than 50 nucleotides upstream of the 3'most exon-exon junction.

Mutations in the ERLIN2 genes can cause three-dimensional morphogenesis to be affected. Matrigel ERLIN2-expressing cellular cells forms disorganized, hollow acini containing filled lumens. However, the same cells that have been mutated can still produce acini with normal copies of DNA. ERLIN2 is therefore not specific to breast cancer cells.

The ERLIN2 genome encodes a gene that binds PI(3)P. However it is not fully understood. However chimeras have shown it interacts both with IP3Rs (and PI(3)P). Therefore, further research is required to understand the function of this complex within living cells. Further research could reveal more about the ERLIN1/2 complex if it is done.

ERLIN2 is important for its role in breast carcinoma. It also plays a vital role in cell proliferation and transforming phenotypes. Breast cancer is linked with its overexpression. These studies suggest that ERLIN2 may play a crucial role in determining breast carcinoma risk. However, it is essential to fully understand the role of this protein in breast-cancer cells.

Histology

The ERLIN2 mark is a marker protein that is expressed within the endoplasmic reticulum. It is a spatially- and developmentally controlled protein that binds to activated Inositoltriphosphate receptors. It is thought that it will be the new medium to ER degradation. It interacts to other proteins in ER, such insulin-induced genes 1 and sterol regulatory factor binding protein 1c.

ERLIN2 is a cyclin-protein interaction that mediates the cell cycle. ERLIN2 expression is low during interphase and Cyclin B1 is reduced. During the M phase, the nuclear membrane breaks down, ER redistributes, and spindle microtubules form. ERLIN2 regulates the cell cycle by interacting with cyclin proteins and microtubule spindles.

Breast cancer cells expressing high levels of ERLIN2 staining expression are often aggressive and invasive. ERLIN2 protein signals are distributed throughout tumor cells and deranged mammary gland epithelial cells. The expression of this gene is important for understanding the molecular mechanisms of tumorigenesis. A drug that inhibits this protein could be developed to benefit cancer patients. Its overexpression can cause breast cancer in children.

ERLIN2 expression occurs in the ER. The peak of ERLIN2 expression is at P7. After that, ERLIN2 expression is undetectable for four months. ERLIN2 is expressed in moderate levels at P1 but then decreases until it is no longer detectable at P15. It was detected by immunofluorescence staining in cerebellum and overlapped NeuN positive cells in this area. ERLIN2 expression cannot be found in other types of neurons.

The overexpression of ERLIN2 in breast cancer cells may facilitate an adaptation of these cells to ER stress. ERLIN2 can protect breast cancer cells against ER-induced apoptosis. This may allow them to grow more selectively. This ability of cells to withstand cellular stresses could explain breast cancer malignancy. Moreover, ERLIN2 knockdown reduces breast cancer cell proliferation.

Primary Antibodies

The ERLIN2 antibody is a versatile marker that can be used for studying gene expression in cell cultures. Its peptide ligand ERLIN2 is a recognized biomarker for a number of autoimmune diseases. This protein can be used in research in many ways. Here are a few of the best uses. The boster biotechnology firm produces the ERLIN2 peptide.

Trusted by the research community

The notion of being trusted by research communities can be ambiguous in the literature. Researchers aren't always aware of both the benefits and the challenges of building trust. Fairness and transparency are also concepts that are difficult to define. Additionally, there are many instances of abuses that have occurred in clinical trials involving human subjects. Examples include the US Public Health Service Syphilis Study of Tuskegee and the 1944 Human Radiation Experiments. Also, there was the ethical misconduct around the HeLa cell lines of Henrietta Lacks. These groups also have lower education attainment than their peers which may lead to dissatisfaction about the research process. These factors are also contributing to the difficulty of forming authentic community-academic partnership.

To foster engagement, it is important to build trust with the research community. It is a complex construct and requires the effort of multiple stakeholders. While it is difficult to define, trust refers to the belief in an individual or an institution's reliability and ability, and is rooted in specific experiences. Trust can be directed to individual researchers or the entire research organization. There are many different ways to develop trust in a community, but the first step is to define what constitutes a trustworthy researcher.

In order to develop trust between researchers and communities, institutions must create robust procedures to deal with potentially suspect findings. Journals must use back and forward links to tie editorial concerns and retractions. Indexing services, as well as other downstream elements, should be regularly updated. Crossref Event Data (or Crossmark) can be used to update data. These two steps are critical for establishing a strong chain of trust.